Type a question in ordinary words. Answers are grounded in retrieved KPSGILL pages and identified sources; questions the library cannot support are declined rather than answered from model memory. No advice is given, and no personal health information is accepted.
531 current articles: 398 policy analyses, 127 patient guides, 3 standing trackers and 3 cross-cutting essays, plus 107 superseded records kept at their original addresses. Ask in your own words.
This week’s records, read at the bodies that issued them. Each carries its instrument, its state and its source — a proposal is not law, an agenda is not a decision, a closed comment period is not a final rule, and an audit finding is not a finding of fraud. Updated 19 August 2026.
Executive orderUnited States · The White House
An order states childhood vaccine recommendations — and directs a plan to split the MMR
Executive Order 14420 recognises recommendations covering 11 diseases on the White House’s own comparison, moves the rest to shared clinical decision-making, and directs HHS to plan for single-disease core vaccines starting with MMR — once such products are domestically available. It amends no schedule, licenses no product, creates no enforceable right and changes no school-entry rule.
EO 14420 · 91 FR 53173 · plans due 8 November · Record
Effective 1 Jan 2027California · DHCS
A whole population leaves managed care — and the deadline lands on the practice
Medi-Cal members with unsatisfactory immigration status move to fee-for-service on 1 January 2027. Eligibility does not change; payment does. A provider not approved through PAVE by that date is unpaid for a patient who is still covered, members are no longer assigned a primary care provider, and Enhanced Care Management and Community Supports do not exist in fee-for-service.
Delivery-system change · enrollment deadline attached · Record
In sessionCalifornia · Medical Board
The Board convenes: panels 19 August, the quarterly meeting 20–21 August
Panel A convened at 9:00 a.m. for oral argument and closed-session deliberation; the quarterly Board meets 20–21 August carrying eighteen legislative positions and the enforcement-timeline audit response. No action on the record yet — outcomes populate from the official record, not the room.
Public meeting · Medical Board of California · Record
Audit findingUnited States · HHS-OIG
The third prior-authorisation audit cuts the other way
Where Kansas and New York produced findings, OIG’s Louisiana audit found the managed-care organisation generally complied with denial-process requirements. Two states with findings, one compliant: an audit program with a spread, not an indictment — and no comment on whether any denial was clinically right.
The MHRA’s position paper places microbiome-based medicinal products inside the existing Human Medicines Regulations — a licensing route for a class aimed squarely at antimicrobial resistance, with zero products yet authorised. FMT for recurrent C. difficile continues unchanged.
Regulatory science · Medicines and Healthcare products Regulatory Agency · Record
Proposed pathwayUnited States · CMS & FDA
Medicare proposes same-day coverage review for breakthrough devices
The RAPID pathway would issue a proposed national coverage determination the same day FDA authorises an eligible Breakthrough Device, with final coverage targeted 60–90 days after authorisation instead of the year or more the gap has run. Coverage evidence expectations would be negotiated during trial design — which is where the real change sits. Comments close 13 October.
Procedural notice CMS-3487-NC · proposed, not operative · Federal Register
National Patient Safety AlertUnited Kingdom · MHRA · with FDA
The UK’s strongest alert class for a home ventilator, on both sides of the Atlantic
A component fault in ResMed Astral 100/150 ventilators can stop ventilation without warning. The MHRA’s safety-critical alert directs executive-led action across every ventilation service; FDA carries the same event as an early alert. Neither regulator says stop using the device — the operative task is a ready backup and caregivers who know the alarm.
NatPSA/2026/004 · 17 August · replacement parts constrained · gov.uk
Docket openUnited States · FDA
FDA opens a public docket on regulating generative-AI medical devices
A discussion paper issued asks how generative-AI devices should be assessed for risk, evaluated before market and monitored after it — including a premarket model built on competency assessment. It is not a rule and not guidance: FDA states it proposes no policy. Feedback to docket FDA-2026-N-7874 closes 19 October.
Discussion paper · FDA Center for Devices and Radiological Health
Comment period closedUnited States · CMS
Medicare drug-price negotiation: the comment period closed on 17 August
The comment period on the proposed rule for the Medicare Drug Price Negotiation Program and the Part D benefit closed . Two state axes move separately: the window is closed and the rule is still a proposal. Nothing became final on that date.
Proposed rule · Centers for Medicare & Medicaid Services
Meeting 19–21 AugCalifornia · Medical Board
Medical Board of California: the quarterly agenda is published
Licensing Panels A and B sit 19 August; the quarterly Board meeting runs 20 and 21 August. Materials are published and the meeting is upcoming — two separate states, neither of them a decision. Records are created for actions the Board actually takes, not for items merely listed.
Bagley-Keene agenda · Medical Board of California
Effective 21 AugustCalifornia · Medi-Cal Rx
Medi-Cal Rx tightens early-refill thresholds for members 21 and older
From 21 August 2026 a refill is blocked where the member has not used enough of the previous fill of the same medication. It reaches the pharmacy counter directly, and the override path matters more than the threshold.
Benefit policy change · DHCS — Medi-Cal Rx
Audit findingUnited States · HHS OIG
OIG projects $15.2 million in improper payments for sacroiliac-joint injections
OIG reviewed sessions billed to Medicare between 1 October 2023 and 30 September 2024. Of a 100-session sample, 72 did not comply with Medicare requirements. An audit finding is not a fraud finding and not a rule change.
Audit report · HHS Office of Inspector General
ConsultationAustralia · TGA
TGA consults on making more of the device record public
A consultation running 13 August to 2 October 2026 on expanding what the TGA may lawfully release about medical devices under section 61 of the Therapeutic Goods Act 1989. A consultation is not a decision.
Consultation · Therapeutic Goods Administration
Accelerated approvalUnited States · FDA
FDA grants accelerated approval to Tudriqev in refractory advanced melanoma
On 6 August 2026 the FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), an HSV-1 oncolytic viral therapy, with nivolumab, for anti-PD-1 refractory disease. Accelerated approval rests on a surrogate endpoint and carries a confirmatory-trial obligation.
Marketing authorisation · Food and Drug Administration
Second state auditUnited States · HHS-OIG
A second state audit asks whether parity reaches prior authorisation
Report A-02-24-01011 puts to New York the question OIG put to Kansas eight days earlier: did the state ensure its Medicaid managed-care plans applied mental-health parity to the authorisation pathway, not just the benefit package. An audit finding is not a fraud finding and imposes no penalty.
Audit finding · HHS Office of Inspector General · Record
Closes 21 AugustAustralia · TGA
Australia’s radiopharmaceutical consultation closes 21 August
The TGA is asking how the regulation of radiopharmaceuticals — medicines used in the diagnosis and treatment of cancer and cardiovascular disease — works in practice. Its listing gives a closing date of 21 August; the consultation’s own information paper gave 31 July, so the window moved out. A consultation is not a decision.
Consultation · Therapeutic Goods Administration · Record
Closes 30 AugustEuropean Union · EMA
Europe reopens a guideline because quitting-smoking medicines were never studied in vaping
EMA’s concept paper records that its smoking-cessation guideline is neither intended for nor fully applicable to dependence on nicotine delivered without combustion — and is being applied to it anyway. The proposal extends it to all forms of nicotine dependence. A concept paper is not a guideline.
The UK pulls devices from use for a paperwork failure, not a defect
DSI/2026/007 orders devices supplied without valid UKCA or CE certification out of use and into quarantine — blood collection and infusion, surgical and biopsy, wound care, skin preparation. The MHRA states plainly that it found no defect, no performance issue and no safety signal. What is missing is the assurance certification is supposed to provide.
Device safety information · Medicines and Healthcare products Regulatory Agency · Record
RecallCanada · Health Canada
Pregabalin capsules recalled in Canada for containing an antidepressant
Two lots of Teva-Pregabalin 150 mg were recalled for cross-contamination with sertraline — not a dosing deviation but a different medicine entirely, which is why it matters most for patients already taking a serotonergic drug. An intravenous fluid and a cuffed endotracheal tube were recalled in the same week.
Every page names its reviewing physician and its review date. Where claim-level authority has been mapped, the evidence can be inspected directly, down to the instrument each proposition rests on. Nothing is deleted. Superseded analyses remain at their own addresses, marked as superseded and pointing to the current record, with its original text retained. Editorial standards & ledger